-
Posted by
Two Blokes Jul 15 -
Filed in
Stock
-
2 views
Arcellx, Inc. is advancing its lead CAR-T therapy, anito-cel, for relapsed/refractory multiple myeloma, with the pivotal phase 3 iMMagine-3 trial underway. Recent positive phase 2 iMMagine-1 data support the potential of anito-cel, especially in 2nd-line+ multiple myeloma patients who failed prior therapies. The FDA has allowed a dual primary endpoint—progression-free survival and MRD-negativity—in the ongoing phase 3 iMMagine-3 study, enhancing regulatory prospects.
